Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Pemigatinib With or Without Immunotherapy in Advanced Malignancies
jRCT2031210587Completed
- Sponsor
- Incyte
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Open-label trial of pemigatinib in Non-hematologic malignancy and hematopoietic malignancies (3 arms), sponsored by Incyte. Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs). Started Feb 2022; status: completed.
02
Drugs
pemigatinib
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on jRCT2031210587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210587.